News

Inflammation markers calculated from routine blood tests, such as ratios of different types of immune cells and a combined inflammation index, appear to increase when ANCA-associated vasculitis (AAV) is more active, a study found. Even though these markers are not specific to AAV, they “may serve as potential supportive…

A study linked high levels of a blood protein called CXCL6 with lung disease in people with ANCA-associated vasculitis (AAV), pointing to the protein as a potential biomarker to diagnose the condition and monitor its progression. Data indicate that people with AAV who have inflammatory lung disease tend to…

More than one-third of patients with newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) already have serious heart disease, a study found. The research also identified coronary artery spasms, sudden episodes of tightening in the heart’s blood vessels that reduce blood flow and can mimic a heart attack, as…

The first participant with ANCA-associated vasculitis (AAV) has been dosed in a Phase 1 clinical trial testing prulacabtagene leucel (prula-cel, formerly ADI-001), Adicet Bio’s experimental CAR T-cell therapy, in people with autoimmune diseases. All seven disease groups in the Phase 1 trial (NCT06375993) are now actively enrolling participants at…

Tavneos (avacopan), in combination with standard treatment, induced disease remission within six months in nearly all adults with ANCA-associated vasculitis (AAV), according to pooled results from 16 published real-world studies. Real-world remission rates with Tavneos at six months and one year were higher than those reported in the…

People with overlapping features of granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA), two types of ANCA-associated vasculitis, may exhibit distinct disease characteristics that influence disease severity and prognosis, a study reveals. By analyzing data from more than 100 people with overlapping GPA/EGPA features, a team…

Risk factors for relapse in ANCA-associated vasculitis (AAV) appear to differ depending on treatment phase, with higher levels of inflammation and immune activity linked to a greater risk of relapse after maintenance therapy is stopped. That’s according to a new, non-prespecified analysis of data from the Phase 3…

Small particles loaded with manganese, an essential trace mineral, may help protect the kidneys from damage related to ANCA-associated vasculitis (AAV) by restoring antioxidant defenses and blocking a form of immune-mediated cell death. These findings come from experiments using neutrophils isolated from the blood of people with ANCA-associated glomerulonephritis…

Blood levels of calprotectin and urine levels of soluble CD163, two biomarkers of inflammation and disease activity in people with ANCA-associated vasculitis (AAV), are elevated within the first six months following an AAV relapse, stabilizing thereafter. That’s according to a recent study in Spain that also showed levels of…

Measuring immune cells called eosinophils can help predict the presence and severity of peripheral neuropathy (damage to nerves outside the brain and spinal cord) in people with eosinophilic granulomatosis with polyangiitis (EGPA), a study showed. In people with one of the other two types of ANCA-associated vasculitis (AAV) —…